Prognostic value of BRAF mutations in localized cutaneous melanoma

J Am Acad Dermatol. 2014 May;70(5):858-62.e1-2. doi: 10.1016/j.jaad.2013.10.064. Epub 2014 Jan 2.


Background: BRAF mutations are frequent in melanoma but their prognostic significance remains unclear.

Objective: We sought to further evaluate the prognostic value of BRAF mutations in localized cutaneous melanoma.

Methods: We undertook an observational retrospective study of 147 patients with localized invasive (stages I and II) cutaneous melanomas to determine the prognostic value of BRAF mutation status.

Results: After a median follow-up of 48 months, patients with localized melanomas with BRAF-mutant melanomas exhibited poorer disease-free survival than those with BRAF-wt genotype (hazard ratio 2.2, 95% confidence interval 1.1-4.3) even after adjustment for Breslow thickness, tumor ulceration, location, age, sex, and tumor mitotic rate.

Limitations: The retrospective design and the small number of events are limitations.

Conclusions: Our findings suggest that reappraisal of clinical treatment approaches for patients with localized melanoma harboring tumors with BRAF mutation might be warranted.

Keywords: BRAF; NRAS; localized; melanoma; prognosis; survival.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease-Free Survival
  • Humans
  • Kaplan-Meier Estimate
  • Melanoma / genetics*
  • Melanoma / pathology
  • Mutation
  • Neoplasm Invasiveness
  • Prognosis
  • Proportional Hazards Models
  • Proto-Oncogene Proteins B-raf / genetics*
  • Retrospective Studies
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology


  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf